What Wearables Show With GLP1 Use

Why It Matters

Wearable‑derived heart‑rate data can identify patients who react poorly to GLP‑1 drugs, allowing clinicians to intervene early and tailor treatment, thereby maximizing therapeutic gains and minimizing risk.

Key Takeaways

• GLP-1 drugs raise resting heart rate modestly, ~2-3 bpm.
• Heart rate variability typically declines with GLP-1 therapy.
• Most users experience no adverse effects despite these biometric shifts.
• Significant RHR increase and HRV drop may signal intolerance.
• Wearable alerts help identify outlier responses, guiding clinical follow‑up.

Summary

The video discusses how wearable devices are revealing subtle cardiovascular changes in patients using GLP‑1 receptor agonists. It highlights that these drugs generally cause a modest rise in resting heart rate—typically a few beats per minute—and a concurrent dip in heart‑rate variability, a metric linked to autonomic balance.

For the majority of users, these shifts are clinically insignificant; they remain healthier overall, with improved weight, glycemic control, and subjective well‑being. However, a subset of patients experiences a disproportionate increase in resting heart rate and a sharper decline in HRV, correlating with reports of feeling “really terrible.” The speaker notes the difficulty in disentangling whether the symptoms stem from the medication’s physiological impact or other factors.

He cites real‑world examples where individuals, alerted by their wearables, flagged abnormal trends and sought medical advice. In such cases, clinicians must weigh the biometric data against symptomatology to decide whether to adjust dosage, switch agents, or investigate alternative causes.

The broader implication is that continuous monitoring can serve as an early warning system, enabling personalized management of GLP‑1 therapy and potentially preventing adverse outcomes while preserving the drug’s metabolic benefits.

Original Description

This is something I'm seeing a bit more now. People are being alerted by their wearables when they start a GLP-1. Resting heart rate goes up a few beats per minute. HRV tends to go down — the not desirable direction. For most people, this is of no meaningful consequence. They're in a better spot being on the medicine." The wearable is telling you something went wrong. The wearable is wrong. Full episode linked